ro 31-8220 has been researched along with Cancer of Prostate in 2 studies
Ro 31-8220: a protein kinase C inhibitor
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, Y | 1 |
| Xue, M | 1 |
| Zhao, X | 1 |
| Yuan, J | 1 |
| Liu, X | 1 |
| Huang, J | 1 |
| Zhao, Z | 1 |
| Li, H | 1 |
| Xu, Y | 1 |
| Flescher, E | 1 |
| Rotem, R | 1 |
2 other studies available for ro 31-8220 and Cancer of Prostate
| Article | Year |
|---|---|
Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indol | 2013 |
Protein kinase C epsilon mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells.
Topics: Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Diterpenes; Enzyme Inhi | 2002 |